• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Formic acid induces hypertension-related hemorrhage in hSSAO < sup > TG < /sup > in mice and human
In this study, 42 hemorrhagic patients with hypertension and hyperlipidemia and 42 age-matched healthy controls were enrolled. The contents of serum semicarbazide-sensitive amine oxidase (SSAO) and formic acid (FC, FC is a final product of SSAO through the oxidation of endogenous formaldehyde, which results from the enzymatic oxidative deamination of the SSAO substrate, methylamine) were examined in the patients after stroke. Hemorrhagic areas were quantified by computer tomography. In the animal study, hemorrhagic degree was assessed by hemotoxylin & eosin or tissue hemoglobin kits. The relationship between FC and blo...
Source: Experimental Neurology - August 21, 2022 Category: Neurology Authors: Ya-Lan Di Yan Yu Sheng-Jie Zhao Nayan Huang Xue-Chao Fei Dan-Dan Yao Li Ai Ji-Hui Lyu Rong-Qiao He Jian-Jun Li Zhi-Qian Tong Source Type: research

A Novel Homozygous Non-sense Mutation in the Catalytic Domain of MTHFR Causes Severe 5,10-Methylenetetrahydrofolate Reductase Deficiency
Conclusion: We identified a novel non-sense mutation in MTHFR gene in a single Egyptian family with severe MTHFR deficiency. The present investigation is clinically important, as it adds to the growing list of MTHFR mutations, which might help in genetic counseling of families of affected children and proper genotype-phenotype correlation. Background Severe 5,10-Methylenetetrahydrofolate reductase (MTHFR; OMIM 236250) deficiency is a rare inborn error of metabolism and inherited in an autosomal recessive fashion. It is a very common disorder of folate metabolism and is clinically characterized with low plasma methion...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research

Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1 α Stabilization
AbstractThe constant failure of single-target drug therapies for ischemic stroke necessitates the development of novel pleiotropic pharmacological treatment approaches, to effectively combat the aftermath of this devastating disorder. The major objective of our study involves a multi-target drug repurposing strategy to stabilize hypoxia-inducible factor-1 α (HIF-1α) via a structure-based screening approach to simultaneously inhibit its regulatory proteins, PHD2, FIH, and pVHL. Out of 1424 Food and Drug Administration (FDA)-approved drugs that were screened, folic acid (FA) emerged as the top hit and its binding potential...
Source: Molecular Neurobiology - October 5, 2018 Category: Neurology Source Type: research

A genetic deficiency in folic acid metabolism impairs recovery after ischemic stroke.
Abstract Stroke is a leading cause of disability and death world-wide and nutrition is a modifiable risk factor for stroke. Metheylenetetrahydrofolate reductase (MTHFR) is an enzyme involved in the metabolism of folic acid, a B-vitamin. In humans, a polymorphism in MTHFR (677C→T) is linked to increased risk of stroke, but the mechanisms remain unknown. The Mthfr+/- mice mimic a phenotype described in humans at bp677. Using this mouse model, the aim of this study was to investigate the impact of MTHFR deficiency on stroke outcome. Male Mthfr+/- and wildtype littermate control mice were aged (~1.5-year-old) and tr...
Source: Experimental Neurology - July 25, 2018 Category: Neurology Authors: Jadavji NM, Emmerson JT, Shanmugalingam U, MacFarlane AJ, Willmore WG, Smith PD Tags: Exp Neurol Source Type: research

B vitamins in stroke prevention: time to reconsider
Publication date: September 2017 Source:The Lancet Neurology, Volume 16, Issue 9 Author(s): J David Spence, Qilong Yi, Graeme J Hankey B vitamin therapy lowers plasma total homocysteine concentrations, and might be a beneficial intervention for stroke prevention; however, cyanocobalamin (a form of vitamin B12) can accelerate decline in renal function and increase the risk of cardiovascular events in patients with impaired renal function. Although early trials did not show benefit in reduction of stroke, these results might have been due to harm in participants with impaired renal function. In patients with diabetic nephro...
Source: The Lancet Neurology - August 9, 2017 Category: Neurology Source Type: research

B vitamins and cognition in subjects with small vessel disease: A Substudy of VITATOPS, a randomized, placebo-controlled trial
VITAmins TO Prevent Stroke (VITATOPS) study, a randomized, double-blind international multi-centre trial involving 8164 subjects in studying effect of lowering homocysteine level by daily administration of B-vitamins (2mg folic acid, 25mg vitamin B6, and 0.5mg vitamin B12) failed to demonstrate a positive effect of B-vitamins in reducing incidence of major vascular events and global cognition decline as measured by mini-mental state examination (MMSE) score [1,2]. However, assessment of cognition using MMSE alone has its limitations and a full neuropsychological assessment of different cognitive domains will provide more robust evidence.
Source: Journal of the Neurological Sciences - May 30, 2017 Category: Neurology Authors: Simon Kang Seng Ting, Arul Earnest, Huihua Li, Shahul Hameed, Hui Meng Chang, Christopher Li Hsian Chen, Eng-King Tan Tags: Letter to the Editor Source Type: research

Folic Acid Therapy Reduces the First Stroke Risk Associated With Hypercholesterolemia Among Hypertensive Patients Clinical Sciences
Background and Purpose—We sought to determine whether folic acid supplementation can independently reduce the risk of first stroke associated with elevated total cholesterol levels in a subanalysis using data from the CSPPT (China Stroke Primary Prevention Trial), a double-blind, randomized controlled trial.Methods—A total of 20 702 hypertensive adults without a history of major cardiovascular disease were randomly assigned to a double-blind daily treatment of an enalapril 10-mg and a folic acid 0.8-mg tablet or an enalapril 10-mg tablet alone. The primary outcome was first stroke.Results—The median treatment durat...
Source: Stroke - October 23, 2016 Category: Neurology Authors: Qin, X., Li, J., Spence, J. D., Zhang, Y., Li, Y., Wang, X., Wang, B., Sun, N., Chen, F., Guo, J., Yin, D., Sun, L., Tang, G., He, M., Fu, J., Cai, Y., Shi, X., Ye, P., Chen, H., Zhao, S., Chen, M., Gao, C., Kong, X., Hou, F. F., Huang, Y., Huo, Y. Tags: Clinical Studies, Diet and Nutrition, Primary Prevention, Hypertension, Ischemic Stroke Original Contributions Source Type: research

The China Stroke Secondary Prevention Trial (CSSPT) protocol: a double‐blinded, randomized, controlled trial of combined folic acid and B vitamins for secondary prevention of stroke
DiscussionThis is the first multicenter randomized trial of secondary prevention for ischemic stroke in a Chinese population with a higher homocysteine level but without folate food fortification.
Source: International Journal of Stroke - March 12, 2013 Category: Neurology Authors: Xuedong Liu, Ming Shi, Feng Xia, Junliang Han, Zhirong Liu, Bo Wang, Fang Yang, Li Li, Songdi Wu, Ling Wang, Nan Liu, Yali Lv, Gang Zhao Tags: Protocols Source Type: research